Nanjing International DMPK Symposium Co-organized by CSSX and Jiangsu Value
The 9th Nanjing International DMPK Symposium was held in Nanjing on Jun. 28. This annual event was undertaken by Jiangsu Value – a platform engaged in the radiopharmaceutical pharmacokinetics and biospecimen analysis under the control of YeeDo ZenCom. The Nanjing International DMPK Symposium has been committed to promoting the development of pharmacokinetics in China, introducing the up-to-date overseas technologies for pharmacokinetics research, assisting the domestic pharmaceutical companies in reaching the international standards for IND DMPK studies, and establishing the effective platform for the direct exchange with the leading pharmacokinetics experts.
Dr. Hu Zhuohan, the committee member of CSSX, delivered a speech at the opening ceremony and issued the letters of employment to the CSSX members. Ms. Wang Yuzhu from the Statistics and Clinical Pharmacology Department, NMPA CDE, illustrated the core significance of pharmacokinetics to the drug research and development. The industry elites gathered together to lively discuss about the cutting-edge issues, including the keynote speeches on cell therapy, gene therapy, and new modality, such as ADCs, bispecific antibodies, monoclonal antibody agents and siRNA.
Dr. Wang Yuzhu
Dr. Gu Zheming
Dr. Chen Linzhi
Dr. Liang Yali
Enthusiastic discussions in the venue
Dr. Gu Zheming
Dr. Gu Zheming, the committee member of CSSX, introduced the “Progress of ADME Test with Radioactive (14C) in China”. The test mainly aims to define the existence of a high proportion of any circulating metabolite in human body.
Dr. Chen Linzhi, in charge of the new drug development in Boehringer Ingelheim (BI), shared his development experience of oligonucleotide drugs in view of DMPK and bioanalysis.
Dr. Liang Yali
Dr. Liang Yali from Bristol-Myers Squibb introduced the application of clinical pharmacology in the drug development and analyzed the living examples.
Enthusiastic discussions in the venue
YeeDo ZenCom
As a professional CRO service provider, YeeDo ZenCom has been highly appreciated by more and more pharmaceutical enterprises due to its technical expertise and humanized services. For the purpose of the high-quality and efficient services, YeeDo ZenCom has built itself into an integrated CRO platform in support of the technical services for clinical research, technical services for entrusted research, technical consultation and registration management services, quality management services, radiopharmacokinetics and biospecimen analysis services, and data management and statistical analysis services by continuously expanding its team and perfecting its industry chain.
